Pulmonary Fibrosis Treatments: Cellcept (Mycophenolate Mofetil)

LUNG (PULMONARY): MAIN MENU

Pulmonary Fibrosis

This page was written by Shelley Ensz, and has not yet been medically edited. See Disclaimer.

Pulmonary Fibrosis Treatments: Cellcept

Mycophenolate Mofetil (Cellcept)

Effect of Mycophenolate Mofetil (MMF) on Pulmonary Function in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD). These retrospective data suggest MMF improves vital capacity (VC) in patients with SSc-ILD. (PubMed) Chest. 2007 Dec 10. (Also see: Cellcept)

Pulmonary Fibrosis In Systemic Sclerosis (SSc) And Dermatomyositis (DM) Demonstrates Marked Improvement After Administration Of Mycophenolate Mofetil (MMF/Cellcept). MMF's immunomodulatory and inhibitory effects on fibroblasts and other non-immune cells and a well established low side effect profile with high tolerance make MMF a potential alternative to cyclophosphamide in the treatment of SSc or DM related interstitial lung disease. L. A. Saketkoo THU0315 EULAR 2007. (Also see: Dermatomyositis)

Mycophenolate mofetil (Cellcept) is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related (CTD) Interstitial lung disease (ILD). Glucocorticoids and immunomodulatory agents are regarded as mainstays of therapy for CTD-related ILD; however, apart from those studies that have evaluated certain medications for patients with scleroderma, few studies have been performed. PubMed. Chest. 2006 Jul;130(1):30-6. (Also see: Medications)

Mycophenolate mofetil (Cellcept) as first-line treatment improves clinically evident early scleroderma lung disease. Our preliminary data suggest that in patients with dSSc and recent, clinically apparent alveolitis, early treatment with Cellcept and small doses of corticosteroids may represent an effective, well-tolerated and safe alternative therapy. PubMed. Rheumatology (Oxford). 2006 Feb 20. (Also see: Medications)